Frazier Life Sciences funds report material holdings in Maze Therapeutics common stock. Frazier Life Sciences Public Fund, L.P. directly holds 3,352,915 shares, equal to 7.7% of the outstanding class. Other reporting entities include Frazier Life Sciences Public Overage Fund, L.P. with 989,351 shares (2.3%), Frazier Life Sciences X, L.P. with 75,982 shares (0.2%), and Frazier Life Sciences XI, L.P. with 149,026 shares (0.3%). Percentages are calculated using 43,797,166 shares outstanding as reported by the issuer.
The filing clarifies voting and dispositive arrangements: several entities report shared voting and dispositive power over the disclosed shares, and James N. Topper and Patrick J. Heron share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The Statement expressly corrects prior attributions and overstatements of beneficial ownership for certain members and includes a certification that the securities are not held for the purpose of changing or influencing control of the issuer.
Positive
Frazier Life Sciences Public Fund, L.P. disclosed 3,352,915 shares representing 7.7% of MAZE common stock
The filing corrects prior attributions and clarifies shared voting and dispositive power across the reporting entities, improving transparency
Negative
None.
Insights
TL;DR: Frazier funds disclose a passive but material 7.7% stake in MAZE and correct prior ownership attributions.
The filing shows Frazier Life Sciences Public Fund, L.P. holds 3,352,915 shares (reported as 7.7% of the class) and several related funds report additional smaller stakes. The use of Schedule 13G-type disclosure and an explicit certification indicates these holdings are presented as passive in nature. The Statement also corrects earlier attributions, limiting prior overstatements of individual members' beneficial ownership. For investors, the key facts are the disclosed share counts, the clarified allocation of voting and dispositive power across entities, and the passive intent stated by the filers.
TL;DR: Corrections clarify who legally holds voting/dispositive power; no claimed intent to affect issuer control.
The filing documents governance-related details: multiple funds are managed by investment committees that act by majority vote, and the Statement expressly disclaims attributing committee members with beneficial ownership of the funds' holdings. It corrects prior over-attributions and clarifies that certain partners do not individually hold the reported shares. The Statement's certification that the positions were not acquired to influence control reinforces the passive disclosure posture, while the clarified shared voting/dispositive power provides clarity on who may exercise influence over these positions.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
Maze Therapeutics, Inc.
(Name of Issuer)
Common Stock - par value $0.001 per share
(Title of Class of Securities)
578784100
(CUSIP Number)
06/30/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,352,915.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,352,915.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,352,915.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.7 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
FHMLSP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,352,915.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,352,915.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,352,915.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.7 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
FHMLSP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,352,915.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,352,915.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,352,915.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.7 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Frazier Life Sciences Public Overage Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
989,351.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
989,351.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
989,351.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
FHMLSP Overage, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
989,351.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
989,351.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
989,351.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
FHMLSP Overage, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
989,351.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
989,351.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
989,351.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.3 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Frazier Life Sciences X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
75,982.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
75,982.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
75,982.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
FHMLS X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
75,982.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
75,982.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
75,982.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
FHMLS X, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
75,982.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
75,982.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
75,982.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Frazier Life Sciences XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
149,026.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
149,026.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
149,026.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
FHMLS XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
149,026.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
149,026.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
149,026.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
FHMLS XI, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
149,026.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
149,026.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
149,026.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
James N. Topper
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
75,982.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
75,982.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
75,982.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of 75,982 shares of Common Stock held directly by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Patrick J. Heron
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
75,982.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
75,982.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
75,982.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of 75,982 shares of Common Stock held directly by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based on 43,797,166 shares of Common Stock outstanding on May 8, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025.
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Albert Cha
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
James Brush
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Daniel Estes
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Maze Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
171 Oyster Point Blvd., Suite 300, South San Francisco, CA, 94080.
Item 2.
(a)
Name of person filing:
The entities and persons filing this statement (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF")
FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
Albert Cha ("Cha")
James Brush ("Brush")
Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")
(b)
Address or principal business office or, if none, residence:
The address and principal business office of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
(c)
Citizenship:
The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.
(d)
Title of class of securities:
Common Stock - par value $0.001 per share
(e)
CUSIP No.:
578784100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference.
FLSPF directly holds 3,352,915 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
FLSPOF directly holds 989,351 shares of Common Stock. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
FLS X directly holds 75,982 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.
FLS XI directly holds 149,026 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.
(b)
Percent of class:
The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Frazier Life Sciences Public Fund, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:
08/14/2025
FHMLSP, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:
08/14/2025
FHMLSP, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:
08/14/2025
Frazier Life Sciences Public Overage Fund, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
Date:
08/14/2025
FHMLSP Overage, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
Date:
08/14/2025
FHMLSP Overage, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Date:
08/14/2025
Frazier Life Sciences X, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:
08/14/2025
FHMLS X, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:
08/14/2025
FHMLS X, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date:
08/14/2025
Frazier Life Sciences XI, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:
08/14/2025
FHMLS XI, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:
08/14/2025
FHMLS XI, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:
08/14/2025
James N. Topper
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:
08/14/2025
Patrick J. Heron
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:
08/14/2025
Albert Cha
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:
08/14/2025
James Brush
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:
08/14/2025
Daniel Estes
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
Date:
08/14/2025
Exhibit Information
Exhibit 99.1 Joint Filing Agreement, dated as of April 29, 2025, incorporated by reference into this Statement.
Who filed the Schedule 13G/A for Maze Therapeutics (MAZE)?
A group of related Frazier Life Sciences entities filed the statement, including Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences Public Overage Fund, L.P., Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P., and related general partner and management entities.
How many MAZE shares does Frazier Life Sciences Public Fund, L.P. hold and what percent is that?
3,352,915 shares, representing 7.7% of MAZE common stock based on 43,797,166 shares outstanding as reported by the issuer.
Do the filers claim any intent to change or influence control of Maze Therapeutics (MAZE)?
No. The filing includes a certification stating the securities are not held for the purpose of or with the effect of changing or influencing control of the issuer.
Did the filing correct any prior errors about ownership attribution?
Yes. The Statement explicitly corrects prior attributions and overstatements of beneficial ownership for certain members and investment committee participants.
Who shares voting or investment power over specific MAZE holdings?
James N. Topper and Patrick J. Heron are disclosed as sharing voting and investment power over the 75,982 shares held by Frazier Life Sciences X, L.P.; several other entities report shared voting and dispositive power over their respective holdings.
